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Cells comprising the immune system are conditioned to respond rap-
idly and vigorously to antigenic and inﬂammatory signals, a process that
heightens cellular metabolism and requires energy. Experiments using
cell culture systems show that the glucose transporter Glut1, an integral
membrane protein that mediates glucose uptake into the cell, is required
for efﬁcient HIV infection of CD4+ T cells (Loisel-Meyer et al., 2012) and
is amarker of CD4+Tcellmetabolic activity (Palmer et al., 2014a).More-
over, the number of CD4+ T cells that express Glut1 is increased in HIV-
infected, treatment-naïve persons. This was reduced during suppressive
antiretroviral therapy (ART) but was not completely normalized when
compared to uninfected individuals. High circulating levels of these
cells is associated with immune activation and a low CD4+ T cell count
in patients, irrespective of treatment status (Palmer et al., 2014a).
Macintyre and co-workers have demonstrated that Glut1 is required for
CD4+ T cell activation and effector functions, and that Glut1 is critical
for the transitioning from oxidative phosphorylation to aerobic glycol-
ysis (Macintyre et al., 2014). Additionally, Oestreich et al., have recent-
ly shown that glycolysis is tightly controlled by the transcription
repressor Bcl-6, which suppresses genes encoding molecules important
in the glycolytic pathway in T cells (Oestreich et al., 2014). This dem-
onstrates additional levels of metabolic control other than the canonical
PI3K–Akt–mTOR axis, an intracellular signaling pathway that regulates
glucose metabolism post-transcriptionally (Powell et al., 2011; MacIver
et al., 2013; Palmer et al., 2015a).
Despite increasing awareness regarding the signiﬁcance of HIV and
growth cytokines in regulating glucose metabolism (Loisel-Meyer
et al., 2012; Palmer et al., 2015b; Locasale and Cantley, 2011;
Dagenais-Lussier et al., 2015), the physiological control of metabolism
in immune cells in HIV infected persons has not been thoroughly inves-
tigated. However, new evidence indicates that intracellular redox state
may exert metabolic control in T cells and monocytes during HIV infec-
tion (discussed in detail below). Indeed, it has long been proposed
that augmented oxidative stress in HIV-infected individuals leads to ac-
celerated disease progression, leading to suggestions that antioxidants
might have a role in improving patients' health (Kotler, 1998). This
review will discuss the recent advances in immunometabolism in the
context of HIV and discusses how redox signaling may regulate key
metabolic checkpoints in T cells and monocytes during HIV infection.
2. The Role of Glucose Metabolism in HIV Pathogenesis
2.1. Glucose Metabolism in CD4+ T Cells During HIV Infection
Data showing that CD4+ T cell metabolic activity is critical for HIV
infectivity and immune activation is now gaining greater impact with
increasing evidence that T cell activation shares an intimate association
with metabolism (Hegedus et al., 2014). The well-established dogma is
that activated CD4+ T cells are preferential targets for HIV infection.Activation of CD4+T cells is accompanied bymetabolic reprogramming
which involves a switch fromoxidativemetabolism in resting cells to in-
tensiﬁed glucose metabolism via aerobic glycolysis (Palmer and Crowe,
2012). Indeed, Macintyre and colleagues have revealed that Glut1 is es-
sential for metabolic programming of CD4+ T cell activation, expansion
and survival (Macintyre et al., 2014). Glycolysis results in the production
of pyruvate fromglucosewith only a net of two adenosine triphosphates
(ATPs) per molecule of glucose. By contrast if pyruvate proceeds
through the tricarboxylic acid cycle (TCA cycle) to oxidative phosphory-
lation, an additional 36 ATP molecules are produced. This suggests
a rather inefﬁcient utilization of glucose, energetically, by activated
CD4+ T cells which have a markedly increased demand for energy.
Glycolysis also diverts the use of glucose for macromolecular biosynthe-
sis essential for cell growth, proliferation, differentiation and mainte-
nance of an activated state (MacIver et al., 2013). Distinct metabolic
programming will also affect the levels of metabolites that can directly
regulate immune cell functions (Loftus and Finlay, 2016).
The signiﬁcance of glucosemetabolic pathways in regulating HIV in-
fection in CD4+T cells has long been recognized. Early work by Sorbara
et al. hinted at the signiﬁcance of glucose metabolism in HIV infection
by demonstrating that HIV infection of the H9 human T cell line in-
duced the expression of Glut1 and Glut3 and increased glucose uptake
(Sorbara et al., 1996). Further support came from Hollenbaugh and col-
leagueswho found that HIV infection of primary CD4+T cells in culture
resulted in increased glucose uptake and expanded levels of glycolytic
intermediates (Hollenbaugh et al., 2011). More link between glucose
metabolism and HIV infection was established by Loisel-Myer et al.,
who showed that increased Glut1 expression on CD4+T cells in culture
increased cellular permissivity to HIV-1 infection, and that suppression
of glucose metabolism by PI3K inhibitors inhibited infection (Loisel-
Meyer et al., 2012). Although Loisel-Myer's group utilized LY294002,
the non-selective isoform and non-tissue speciﬁc PI3K inhibitor, their
results demonstrated that the PI3K pathway at least in part regulates
glucose metabolism in CD4+ T cells. The PI3Kγ isoform has been pro-
posed as potentially involved in glucose metabolic regulation in im-
mune cells, but it's involvement in HIV infectivity is unclear (Palmer
et al., 2015b). The signiﬁcant relationship between metabolism in im-
mune cells and HIV pathogenesis in humans has been elegantly
reviewed recently by Dagenais-Lussier and co-workers. They proposed
that dysregulated metabolism including excessive uptake of glucose
by immune cells could induce hyper-immune activation whichmay re-
sult in HIV-related complications (Dagenais-Lussier et al., 2015).
2.2. Link Between Glucose Metabolism in T Cells and HIV Disease
Progression
Inﬂammatory activation of T cells is accompanied by increased ener-
gy requirements via glycolysis, needed for the surge in cytokine produc-
tion and differentiation into Th1 and Th17 cells. Evidence reveal that
the glycolytic intermediate can directly control immune functions. It
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(PEP) is important in sustaining T cell receptor-mediated Ca2+-NFAT
signaling and effector functions (Ho et al., 2015). Although studies sug-
gest that Glut1 is required for metabolic reprogramming of CD4+ T cell
activation, its signiﬁcance in HIV infected individuals and the impact on
disease progression has only recently been studied (Palmer et al.,
2014a). The pathogenesis of HIV disease is characterized by chronic im-
mune activation, inﬂammation and increased oxidative stress. Even in
the presence of effective antiretroviral therapy (ART), chronic immune
activation persists and is associated with, and predictive of, incomplete
CD4+ T cell recovery, as well as increased morbidity and mortality
(Hunt et al., 2011a,b; Deeks, 2009; Fernandez et al., 2011). This persis-
tent chronic immune activation places a high metabolic demand on
CD4+ T cells in HIV infected individuals and cellular metabolic activity
is increased in response to this imposed challenge.
In HIV infected patients there is an intricate immune balance and
function of cellular immune subsets, such as regulatory T cells (Tregs)
and T helper 17 (Th17) cells (Arruvito et al., 2012). Treg cells, character-
ized by Forkhead Box Protein 3 (Foxp3+) expression, are an important
subset capable of suppressing chronic immune activation and expan-
sion of immune cells. Conversely, Th17 cells are characterized by IL-17
production allowing these cells to exert proinﬂammatory function
against extracellular pathogens (Valverde-Villegas et al., 2015).
CD4(+)CD25(+)Foxp3(+) Tregs have reduced ability to activate the
PI3K/Akt pathway, a signaling pathway required for Glut1 expression
and glucose metabolism (Palmer et al., 2015a). Human Tregs regulated
by Foxo3 are unable to up-regulate Glut1 in response to T cell receptor
ligation. Notably, pharmacologic activation of Akt overcomes the effects
of Foxp3 in Tregs and induces Glut1 expression in these cells (Basu et al.,
2015). In contrast, the proinﬂammatory Th17 cells, together with Th1
and Th2 cells express high surface levels of Glut1 and are highly glyco-
lytic (MacIver et al., 2013; Palmer et al., 2015b; Michalek et al., 2011).
A sub-population of CD4+ T cells in humans that expresses Glut1
(CD4+Glut1+) was recently identiﬁed by ﬂow cytometry using
Glut1 antibody MAB1418 clone from R&D Systems, Minneapolis, Minne-
sota, USA (Palmer et al., 2014a). Although the reactivity of the antibody
have been somewhat controversial (Kinet et al., 2007), it's speciﬁcity
has been conﬁrmed by Western Blot and ﬂow cytometry in lentiviral-
infected HEK293T cells overexpressing Glut1. Furthermore, intracellular
Glut1 (Glut1c-term) analysis, using anti-Glut1 Ab40084 (Abcam) con-
ﬁrmed that glucose metabolism is increased in CD4+ T cells in HIV-
infected persons (Palmer et al., 2014a). Other groups have used Glut1-
RBD-GFP from Metafora Biosystems to study Glut1 expression on HIV
infected primary CD4+ T cells (Hegedus et al., 2014). The percentage of
circulating CD4+Glut1+ cells is signiﬁcantly increased in HIV-infected
individuals and is a measure of persistent immune activation as well as
being associated with a low CD4+ T cell count, irrespective of treatment
status. Of note, the frequency of circulating CD4+Glut1+ cells in long-
term non-progressors is similar to those of treated virologically-
suppressed individuals (Palmer et al., 2014a). These CD4+Glut1+ T
cells were highly activated as measured by the co-expression of CD38
and HLA-DR on their cell surface. Although an association between in-
creased glucose metabolism, CD4+ T cell activation and low CD4+ T
cell count has been established in HIV infection, the mechanisms under-
pinning these associations are unclear. It isworthwhile to note that prote-
ase inhibitors such as nelﬁnavir impair Akt signaling andGlut4 expression
on adipocytes, and thus have been linked to Type 2 diabetes and insulin
resistance (Kachko et al., 2009). Their effects on immune cell metabolism
are less clear but have been shown to reduce anti-inﬂammatory gene ex-
pression in peripheral blood mononuclear cells (Yilmaz et al., 2010).
2.3. Metabolic Exhaustion— AModel for CD4+ T Cell Death in HIV -Infect-
ed Individuals
CD4+Tcell depletionduringHIV infection occurs via twomajor path-
ways and has been reviewed (Cox and Siliciano, 2014). Productiveinfection of activated CD4+T cells induces apoptosis,mediated by activa-
tion of both a DNA-dependent protein kinase (DNA-PK) and caspase-3
(Cooper et al., 2013). However, death of non-infected bystander CD4+
Tcells occurs by an abortive infection-induced-pyroptosis, an IL-1βdriven
inﬂammatory process, mediated by caspase-1 activation (Doitsh et al.,
2014). HIV-infected persons whose activated CD4+ T cells exhibit high
glucose metabolic activities display elevated levels of immune activation
and is associated with poor CD4 T cell recovery. These processes may be
linkedwithhigh glucosemetabolic activity having been shown to activate
caspase-3, and IL-1βmediated caspase-1 expression in several cell types
to induce cell death (Ho et al., 2000; Koenen et al., 2011). In untreated in-
dividuals, one potential mechanism by which HIV may dysregulate me-
tabolism is through intracellular expression of Tat101 protein which
suppresses the transcription of mtDNA, resulting in low ATP synthesis
(Rodriguez-Mora et al., 2015).
In HIV+ subjects effectively treated with ART, the percentage of cir-
culating CD4+Glut1+ T cells was more strongly associated with the
absolute CD4+ T cell percentage than the classic markers of T cell acti-
vation, CD38 and HLA-DR (Palmer et al., 2014a). Furthermore
CD4+Glut1+ T cells expressed more PD1 and Annexin V, had higher
levels of activation markers, and had increased glycolytic activity, com-
paredwith CD4+Glut1− cells (Palmer et al., 2014a). Consistent with a
metabolically-exhausted phenotype, CD4+Glut1+ T cells apoptose
more rapidly in culture than CD4+Glut1− T cells (Palmer et al.,
2013). Here we propose a model by which abnormally high glycolytic
metabolism in CD4+ T cells during HIV infection fuels cell death. In
this model we hypothesize that sustained activation of most CD4 effec-
tor T cells results in metabolic exhaustion and cell death for two main
reasons, as follows. Firstly, activated CD4+ T cells have an inherently
low energy reserve — they have a low spare respiratory capacity
(SRC), which means that there is insufﬁcient additional mitochondrial
capacity available to maintain energy under increased stress or virus
production. Thus compared to Tregs, Th1 effector cells have been
shown to have lower SRC (Gerriets et al., 2015). Secondly, the high traf-
ﬁcking of ATP towards biosynthetic reactions (e.g. cell membrane and
DNA synthesis) for CD4+ T cell growth and proliferation outpaces the
amount of ATP generated by oxidative phosphorylation and glycolysis
itself, thus resulting in metabolic exhaustion and cell death (Fig. 1).
Supporting this model, Hegedus and colleague have demonstrated
that glycolytic metabolism is essential for virion production and in-
creases the sensitivity of infected primary CD4+ T cells to apoptosis.
HIV-1 infected primary CD4+ T cells cultured in galactose have in-
creased survival over those cultured in glucose and this was associated
with reduced caspase 3 activation and apoptosis in cultures supple-
mented with galactose (Hegedus et al., 2014).
High-resolution CT and positron emission tomography (PET) scans
have been used to evaluate thymic tissue in HIV aviraemic patients
with poor recovery of CD4+ T cells. This technique involves injection
of glucose tagged with a short-lived isotope (2-[18F]-ﬂuoro-2-deoxy-
D-glucose) ([18F]FDG), and so detect metabolically active tissue. Al-
though FDG PET scans did not discover any metabolically active thymic
tissue, there was detectable activity in the axillary, mediastinal, sub-
mandibular, upper cervical and/or hilar lymph nodes in some patients
(Tanaskovic et al., 2011). More application of this technology may
improve our understanding regarding how immune cell metabolism
in tissues such as lymph nodes and arterial walls may contribute to
HIV disease pathogenesis.
2.4. Role of T Cell Metabolism on HIV-associated Inﬂammation
The relationship between T cell metabolism and chronic inﬂam-
mation during HIV infection is not well understood. An imbalance
in the ratio of circulating levels between the pro-inﬂammatory Th1/
Th17 and anti-inﬂammatory Th2 cells exists during HIV infection
(Fanales-Belasio et al., 2009; Williams et al., 2013). Driven by the
mTORC1 pathway and glycolysis, Th1 and Th17 cells maintain an
Fig. 1.Model illustratingmetabolic exhaustion of CD4+T cells inHIV-infected individuals.
Activation of CD4+ T cells is maintained by increased cell surface Glut1 expression and
glycolysis. We propose a model whereby CD4+ T cells have a low energy reserve and
therefore, prolonged activation results in metabolic exhaustion and cell death. PPP,
pentose phosphate pathway.
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and TNF (Chang et al., 2013; Zheng et al., 2009; Delgoffe et al., 2011).
These cytokines arewell establishedmediators of chronic inﬂammation
in HIV infected individuals.
Human Th17 cells represent a T cell subpopulation that expresses
CCR6, IL-23R and is deﬁned by production of IL-17, as well the lineage-
deﬁning transcription factor RORC2 in humans (Maggi et al., 2010).
Th17 cells are enriched in the gut mucosa where they play a critical
role in maintenance of the mucosal barrier and host defense against ex-
tracellular bacterial and fungal infections (Omenetti and Pizarro, 2015).
Similarly to Th1 populations these cells are highly glycolytic. Th17 cell-
inducing conditions induce glycolytic enzymes and increase glycolytic
activity. Suppression of glycolysis inhibited Th17 development while
promoting Treg cell differentiation. Furthermore, the transcription factor
HIF-1α is selectively expressed in Th17 cells controlled by mTOR, a cen-
tral regulator of glucose metabolism (Shi et al., 2011). Recent evidence
has shown that uncommitted naive T cells have very high metabolic re-
quirements for IL-17 inductions and is dependent on mTOR activity as
the rate-limiting step (Kastirr et al., 2015).
Gerriets and colleagues conducted detailed in vivo and in vitro
metabolic analysis of effector T cells (Teffs; Th1 and Th17) and Tregs
(Gerriets et al., 2015). They demonstrated that inﬂammatory Teffs and
CD4+ Tregs are characterized by distinct metabolic processes. In an
in vivo model of active experimental autoimmune encephalomyelitis,
Th17 cells had elevated levels of Glut1 in the spleen and inguinal
lymph nodes, but not on FoxP3-expressing cells. Furthermore, both
Glut1 and Glut3 were upregulated on Th17 but not Tregs in in vitro po-
larized CD4+CD25− T cells (Gerriets et al., 2015).
Although both Th1 and Th17 were highly glycolytic, Th17 cells
had higher levels of glycolytic genes and intermediates, regulated by
HIF-1α. On the other hand, glycolysis in Th1 cells appeared to be regu-
lated posttranscriptionally without accumulation of glycolytic interme-
diates (Gerriets et al., 2015). Remarkably, suppression of glycolysis
by 2DG prevented Teff proinﬂammatory cytokine production in vitro
and inhibited the transcription factors T-bet and RORγT (Gerriets
et al., 2015; Shi et al., 2011).Unlike Th1 and Th17 cells, Tregs have greater respiratory capacity
andmetabolic plasticity and canmetabolize lipids in addition to glucose.
PDHK selectively regulates CD4+ T cell differentiation and inﬂamma-
tion and its inhibition speciﬁcally impairs Th17 while sparing Th1, and
inducing Treg differentiation (Gerriets et al., 2015). Thus, inhibition of
PDHK1 suppressed RORγT expression and IL-17 production in Th17
cells but had no effect on T-bet expression or IFN-γ production in Th1
cells (Gerriets et al., 2015).
Th17 cells have enhanced permissivity to HIV infection (Cecchinato
et al., 2008; Alvarez et al., 2013), which raises the possibility that they
could contribute to residual viral replication and inﬂammation in the
gut of individuals on effective ART. IL-17 cytokines are induced by
high glucose through involvement of key signaling pathways such as
NF-κB, protein kinase-C, p38 mitogen activated protein kinase; leading
to lymphocyte activation and adhesion to human umbilical vein endo-
thelial cells (Kumar et al., 2014), relevant to the pathogenesis of HIV-
associated complications like atherosclerosis (Maisa et al., 2015).
2.5. CD4+ T Cell Metabolism and Homeostatic Proliferation of HIV
Reservoir
Glut1 expression on CD4+ T cells is essential for their proliferation
and survival and is regulated by growth and inﬂammatory cytokines
such as IL-2 and IL-7. A major HIV reservoir comprises memory
CD4+ T cell subsets: central memory (CD45RA−CCR7+CD27+), ef-
fector memory (CD45RA−CCR7−CD27−) and transitional memory
(CD45RA−CCR7−CD27+−) cells. These memory CD4+ T cells
may harbor active reservoir (cells producing multiply spliced HIV
RNA), latent reservoir (cells containing integrated HIV DNA), or defec-
tive provirus incapable of producing competent HIV virions. Homeo-
static proliferation of these reservoirs creates a major barrier to HIV
eradication. (Chomont et al., 2009).
Genetic characterization ofHIV-1DNA frommemory T cells frompe-
ripheral blood and gut-associated lymphoid tissue (GALT) from eight
HIV-infected patients after 4–12 years of suppressive cART suggests
that continued low levels of virus replication is not the major cause of
HIV persistence in these cell populations (Josefsson et al., 2013). The
authors concluded that the presence of clonal intracellular HIV-1 se-
quences indicated that HIV-1-infected memory T cells homeostatically
proliferate during suppressive therapy (Josefsson et al., 2013). Another
study analyzing env and pol sequences generated following single-
genome ampliﬁcation of virus obtained from blood and sputum of six
HIV-infected individuals during long-term suppressive cART reported
that identical or monotypic HIV-1 DNA sequences increased over time
during ART (Wagner et al., 2013), further suggesting that proliferation
of cells harboringHIV provirus is a keymechanism in HIV-1DNA persis-
tence. Under physiological conditions, memory CD4+ T cells have low
cell surface expression of Glut1 (Palmer et al., 2014a) and undergo
slow turnover (basal homeostatic proliferation) (Purton et al., 2007),
but can divide rapidly in the presence of inﬂammatory cytokines
(acute homeostatic proliferation) (Frison et al., 2013). In HIV-infected
persons, the percentage of circulatingmemory CD4+ T cells expressing
Glut1 is elevated (Palmer et al., 2014a). It is plausible that high levels of
cell survival cytokines such as IL-7, and persisting inﬂammation in
HIV+ART-experiencedpatients keep memory CD4+ T cells in a meta-
bolically primed glycolytic state, promoting additional rounds of prolif-
eration and expanding the HIV reservoir. These discussions invite
research design to establish whether suppression of homeostatic prolif-
eration through targeting glucosemetabolic pathwaysmay be a feasible
strategy to suppress or deplete the HIV reservoir (Palmer and Crowe,
2014a).
Although memory T cells have often been described as “resting”, a
subset of these memory CD4+ T cells expresses intermediate levels of
CD25, suggesting a basal level of cellular activation (Triplett et al.,
2012). This is further supported by our observation that Glut1 level is
signiﬁcantly elevated on memory CD4+ T cell sub-populations in
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2014a). No studies have directly investigated the impact of metabolic
inhibitors on HIV reservoir size, but one investigation has provided
proof-of-concept for potential roles of these drugs inHIV cure strategies.
In an exploratory study evaluating the effect of the mTOR inhibitor
sirolimus onHIV persistence in cART-treatedHIV-infected kidney trans-
plant recipients, Stock and colleagues showed that sirolimus was inde-
pendently associated with lower levels of HIV DNA in CD4+ T cells
(Stock et al., 2014) and suggested their data supported a controlled clin-
ical trial to access the impact of this mTOR inhibitor on HIV persistence
during effective ART (Stock et al., 2014).
2.6. Targeting CD4+ T Cell Metabolism in HIV Cure and Remission
Strategies
The PI3K/Akt signaling pathway, a key regulator of glucose me-
tabolism in immune cells has been shown to have a pivotal role in
the maintenance of HIV-1 latency. A novel agonist of PI3K p110α,
1,2,9,10-tetramethoxy-7H-dibenzo[de,g]quinolin-7-one reactivated
HIV in in vitro models of virus latency and increased HIV expression in
CD8+-depleted blood mononuclear cells from virally-suppressed
HIV-infected persons on suppressive ART. Similarly, the histone
deacetylase (HDAC) inhibitor vorinostat (SAHA) also reactivated HIV
via activation of PI3K/Akt signaling pathway (Doyon et al., 2014).
In other work, Giacomet and colleagues showed an increased
number of activated CD4+ and CD8+ T cells (CD25+, HLA−DR+,
CD69+) in an infant with congenital HIV infection, who, after 3 years
of age, despite repeatedly testing negative for HIV antibodies, HIV
DNA, p24, and HIV RNA was not cured (Giacomet et al., 2014). CD4+
T cells enriched for Th1/17 polarized cells, which have been shown to
be metabolically active under inﬂammatory conditions had elevated
susceptibilities to HIV-1 (Gerriets et al., 2015; Sun et al., 2015). Fur-
thermore it has been postulated that metabolically-active Glut1-
expressing CD4+ T cells are potential targets for HIV (Loisel-Meyer
et al., 2012). Macintyre and colleagues have shown that Glut1 cell sur-
face expression and glycolytic metabolism is selectively essential for
maintaining CD4+ T cells activation (Macintyre et al., 2014). Increased
Glut1 expression and cellular metabolism may increase proliferation
of HIV reservoir cells, and also enhance viral proliferation by providing
ATP substrate for viral DNA replication, and metabolites for cellular
survival and functions (Loftus and Finlay, 2016). Thus therapies toFig. 2. IncreasedGlut1 cell surface expression and glycolysismaintain CD4+T cell activation. Su
reduce activation and therefore limit the number of potential HIV targets.normalize metabolically active cells in scenarios where active HIV is
limited but where activated CD4+ T cells still exist may provide op-
portunity for longer-term remission in virologically suppressed pa-
tients off ART.
In addition, lactate secreted as the end product of aerobic glycolysis
by metabolically active CD4+ T cells, has been shown to suppress the
proliferation and activity of cytotoxic T lymphocytes (Jones and
Peterlin, 1994), which could subdue the ability of by-stander CD8+ T
effector cells to counteract HIV in tissue compartments (Fig. 2)
(Loisel-Meyer et al., 2012; Palmer and Crowe, 2012). Normalization of
metabolic activity of CD4+ T cells may decrease the amount of HIV tar-
gets available in strategies utilizing the “shock and kill” procedure
where CD4+ T cells may be inadvertently become activated
(Rasmussen et al., 2014).
Indeed, it has been proposed that exploiting histone deacetylase in-
hibitors, such as vorinostat that disrupts HIV latency, with programmed
interference in the metabolic stress of infected HIV cells is a potential
strategy to purge the reservoir (Alonso-Villaverde et al., 2013). Metfor-
min, a mitochondrial electron transport chain complex I inhibitor nor-
malizes CD4+ T cell over-reactive metabolism (Yin et al., 2016; Yin
et al., 2015). Metformin and chloroquine are potent modulators of
pro-survival mechanisms to which HIV infected cells are challenged to
generate energy to maintain virus production. While metformin may
suppress cellular biosynthetic machinery by viral genes, chloroquine
contributes to death of infected cells (Alonso-Villaverde et al., 2013).
It raises the question whether combination of deacetylase inhibitors,
metformin, and chloroquine during effective ART may be pursued to
decay the HIV reservoir in patients (Alonso-Villaverde et al., 2013),
however clinical evaluation of this strategy has not been conducted.
Metabolic-modifying drugs may also suppress HIV replication
and spread independent of their immunomodulatory and metabolic
properties. INK128 a dual ATP-competitive inhibitor of mTORC1 and
mTORC2, suppress HIV-1 viremia in humanized mice by inhibiting
the HIV lifecycle at the transcriptional level, while also suppressing
CCR5 expression and R5 HIV entry into CD4+ T cells. Furthermore,
INK128 boosted the antiviral potency of the CCR5 antagonist
Maraviroc, and had favorable synergistic antiviral interactions with
reverse transcriptase, integrase and protease inhibitors (Heredia
et al., 2015). Adopting metabolic-modifying drugs that target cellu-
lar proteins necessary for successful completion of the HIV lifecycle
have an advantage to slow emergence of resistance because cellularppression of the abnormally high levels of glycolysis in CD4+T cellsmaybe an approach to
Fig. 3. Glucose metabolic proﬁles of M1 and M2 macrophages. (A) Glucose metabolic
proﬁle of M1 macrophages. Classically activated macrophages induce aerobic glycolysis
that results in lactate production and increased synthesis and secretion of inﬂammatory
cytokines. (B) Glucose metabolic proﬁle of M2 macrophages. Alternatively activated
macrophages trigger a metabolic proﬁle predominated by oxidative phosphorylation
(OxPhos).
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et al., 2015).
2.7. Metabolic Targeting of the Macrophage HIV Reservoir
As demonstrated by GAPDH, which has posttranscriptional control
over IFNγ expression in T cells (Chang et al., 2013), glycolytic enzymes
do regulate immune cell functions and survival independent of canoni-
cal metabolic pathways. Hexokinase-1 (HK-1) a glycolytic enzyme that
converts glucose to glucose-6-phosphate by aerobic glycolysis plays a
‘non-glycolytic’ role in the survival and maintenance of HIV-1- infected
macrophages by binding tomitochondria andmaintainingmitochondrial
membrane potential. Disruption of the HK-1/mitochondrial interaction
with a pharmacological agent, clotrimazole induced mitochondrial
membrane depolarization, and caspase-3/7-mediated apoptosis (Sen
et al., 2015). This suggests that manipulating this association in persis-
tently infected macrophages may induce virus-associated cell death in
HIV-infected macrophages (Sen et al., 2015).
It appears that HIV-1 hijacks the macrophage glucose metabolism
machinery via Vpr-regulated HIF-1α to induce glycolytic genes such
as HK-1, glucose-6-phosphate dehydrogenase, and pyruvate kinase
muscle type 2 to promote viral replication and cellular biogenesis to
prolong the survival of HIV-infected macrophages (Barrero et al.,
2013). Thus strategies that disrupt transcriptional and posttranscrip-
tional control ofmetabolic regulatorsmay be exploited in combinatorial
approaches for HIV eradication.
3. Metabolic Regulation of Monocytes
Monocytes dramatically change theirmetabolic phenotype from ox-
idative to glycolytic metabolismwhen activated in humans (Dietl et al.,
2010; Cramer et al., 2003), similar to what is observed in T cells. In a
study conducted by Vats and colleagues, classical activation of murine
macrophages by IFNγ and lipopolysaccharide (LPS) strongly induced
glucose uptake with a concomitant suppression of fatty acid uptake
and oxidation (Vats et al., 2006). Evidence suggests that classically
activated pro-inﬂammatory M1 macrophages demonstrate enhanced
glycolytic metabolism and reduced mitochondrial activity. A similar
metabolic proﬁle represents the metabolic basis of “trained immunity”
or “innate immune memory”, in which trained monocytes have in-
creased aerobic glycolysis regulated through an Akt–mTOR–HIF-1α
pathway (Cheng et al., 2014). In contrast, anti-inﬂammatoryM2macro-
phages are characterized by highmitochondrial oxidative phosphoryla-
tion, have enhanced spare respiratory capacity (Van den Bossche et al.,
2015), and are reliant upon β-oxidation of fatty acids (Johnson et al.,
2012; Mills and O'Neill, 2016). However, Hollenbaugh and colleagues
more recently showed that while oxidative metabolism was increased,
glucose uptake and glycolysis were reduced when the monocytic cell
line U1 was infected with HIV (Hollenbaugh et al., 2011). This discrep-
ancy is likely due to differences in activating stimuli and may relate to
the use of cell lines as sources of monocytes, further complicated by
the use of distinct monocytic cell lines U1 and U937 in their experi-
ments. It is possible that, similar to CD4+ T cells, both metabolic
programs are upregulated in monocytes and macrophages during acti-
vation, but glycolysis predominates. From a bioenergetics perspective,
engaging oxidative phosphorylation maximizes ATP production so
whywould activated monocytes engage a less efﬁcient energy generat-
ing pathway? It may be argued that engagement of glycolysis creates
substrates for DNA and cell membrane synthesis to facilitate growth
and differentiation of monocytes. Another possibility for the glycolytic
shift by M1 macrophages is to facilitate optimal response suited for
the rapid, short-term bursts of activation needed at sites of infection
or inﬂammation as discrete metabolic patterns will result in varying
levels of metabolites that can directly impact cellular function (O'Neill
and Pearce, 2016). Citrate accumulation in theM1macrophage is essen-
tial for the production of proinﬂammatory mediators such as NO, ROS,and prostaglandins (Infantino et al., 2011). In addition, metabolites
and intermediates may serve as important signaling or regulatory mol-
ecules in immune cells. For example, the glycolytic enzyme GAPDH can
bind to the AU-rich elementswithin the 3′UTR of IFN-γmRNA in T cells,
and may disengage glycolysis and control effector cytokine production.
Thus, aerobic glycolysis may also serve as a signaling mechanism to
control inﬂammatory responses in immune cells (Chang et al., 2013).
3.1. IncreasedGlut1 Expression SupportsMonocyte Differentiation andMac-
rophage Activation
Although differences in glucose metabolism are apparent between
unactivated and activated monocytes (Palmer et al., 2014b), the meta-
bolic signature of monocytes also varies depending on their differentia-
tion state. The mechanisms governing the transition from activated
monocytes to macrophage are poorly understood, but recent work
byMalide et al., suggests that distinct temporal distribution and expres-
sion kinetics of glucose transporters characterize human monocyte dif-
ferentiation to macrophages. Monocyte activation elicited by phorbol
myristate acetate (PMA) stimulation resulted in Glut1 trafﬁcking to
the plasma membrane and Glut5 redistribution from the plasmamem-
brane to intracellular compartments (Malide et al., 1998). In addition,
LPS-stimulated murinemacrophages showed enhanced glucose uptake
which was attributed to expression of Glut1, the dominant glucose
transporter in macrophages (Fukuzumi et al., 1996). In fact it is pro-
posed that certain subpopulations of monocytes adopt a glycolytic pro-
ﬁle allowing them toprolong their survival in lowoxygen environments
such as sites of chronic inﬂammation and tumors (Roiniotis et al., 2009).
3.2. Is There a Link Between Glucose Metabolism in
Monocytes/Macrophages, Inﬂammation and HIV Infection?
There are currently no established mechanistic links between
increased glucose metabolism in monocytes/macrophages and in-
ﬂammation in HIV-infected individuals. Freemerman and co-authors
illustrated convincingly that Glut1 is the primary rate limiting glucose
transporter on pro-inﬂammatory M1macrophages (Freemerman et al.,
2014). Macrophages that expressed Glut1 secreted high levels of pro-
inﬂammatory mediators such as G-CSF, CXCL1, CXCL2, IL-6, RANTES,
TNF and IL-1RA, and reactive oxygen species (Fig. 3) (Freemerman
et al., 2014).
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regulates IL-6, IL1β and TNF mRNA expression in pro-inﬂammatory
GM-CSF macrophages likely via HIF-1α/HIF-2α regulated genes
(Izquierdo et al., 2015). Because the CCL2/CCR2 axis regulatesmonocyte
recruitment to inﬂammatory sites (Sierra-Filardi et al., 2014) determin-
ing the metabolic factors that control their expression might identify
novel targets for treating of HIV-associated co-morbidities such as ath-
erosclerosis and cardiovascular disease, associated with inﬂammatory
monocyte recruitment into inﬂamed blood vessels (Maisa et al., 2015).
Since activated and pro-inﬂammatory monocytes play a critical role in
HIV-associated co-morbidities, understanding the metabolic regulation
of monocyte activation may provide novel therapeutic opportunities to
improve the care of aging persons living with HIV.
We have shown that Glut1 is elevated on monocytes circulating
in the blood of untreated and treated HIV-infected patients (Palmer
et al., 2014b). Monocytes are currently classiﬁed into three major
sub-populations based on the levels of CD14 andCD16 expression (clas-
sical: CD14++CD16−, non-classical: CD14+CD16++, intermediate:
CD14++CD16+). Compared to classical monocytes, non-classical
and intermediate monocyte subsets have higher frequencies of Glut1-
expressing cells. Higher Glut1 expression may be linked to a metabolic
response to pro-inﬂammatory cytokine synthesis particularly within
the intermediate monocyte population (Palmer et al., 2014b). This in-
cites a scenario by which HIV infection (in treated and untreated indi-
viduals) in the setting of increased glucose metabolism and cellular
activation provokes an inﬂammatory environment that increases the
risk of age-associated co-morbidities. We have proposed a model in
whichmonocyte activation duringHIV infection facilitates a preferential
shift in glucose metabolism from oxidative phosphorylation to aerobic
glycolysis to sustain an inﬂammatory state with differentiation of mac-
rophages into pro-atherogenic foam cells (Fig. 4) (Palmer and Crowe,
2014b). Although this explanation may have weight, experimental
data will inform whether exploitation of drugs that selectively target
glucose metabolic pathways in monocytes may be useful in the treat-
ment of chronic inﬂammation in HIV-infected individuals.Fig. 4. Monocyte metabolic proﬁle changes during activation and differentiation.
Monocytes display distinct metabolic proﬁles depending on their activation and
differentiation states. Unactivated/naive monocytes are metabolically quiescent; their
basal metabolic activity is low and ATP is derived primarily via oxidative phosphorylation
(OxPhos). Upon activation/immune challenge monocytes shift to a state of metabolic
activation characterized predominantly by Glucose transporter 1 expression (Glut1),
increased glucose uptake, elevated glycolysis and biomass accumulation. Transition of
monocytes to macrophage is characterized by further increases in Glut1 expression,
glycolysis and biomass production. Activation of macrophages through ‘trained immunity’
may facilitate their transition to foam cells and instigate atherosclerosis.The increased glycolysis observed during inﬂammatory activation
of myeloid cells is accompanied by a surge in cytokine production
and therefore pathways that regulate glucose metabolism are consid-
ered potential targets to treat inﬂammatory-mediated diseases. Several
studies have highlighted the potential of metabolism-modifying drugs
in treating inﬂammatory conditions. For example, activation of mTOR
contributes to inﬂammatory-driven foam cell formation in patients
with end-stage renal disease (Ma et al., 2014). Rapamycin has been sug-
gested for the treatment of inﬂammatory-related diseases, including
cardiovascular disease (Wullschleger et al., 2006), since it inhibits
mTORC1 inmacrophages (Ai et al., 2014). Using a cell-speciﬁc knockout
approach Ai et al., established a regulatory role for mTORC1 in the
suppression of inﬂammatory chemokines, CCl2 gene expression and
atherogenesis (Ai et al., 2014). A large body of evidence indicate that
other more speciﬁc mTORC1 inhibitors such as everolimus have pleio-
tropic anti-atherosclerotic effects making it a potential candidate as
add-on therapy to prevent or delay the pathogenesis of atherosclerosis
(Martinet et al., 2014).4. Physiological Regulation of Glucose Metabolism: Oxidative Stress
4.1. Role of Redox Signaling in Modulating Inﬂammatory Responses During
HIV Infection
Having described the importance of glucosemetabolism inHIV-1 as-
sociated immune activation and inﬂammation, wewould like to discuss
a unique and underappreciated aspect of cellular physiology; that is, in-
tracellular redox state in exerting genetic and metabolic control on HIV
infection. Since energy metabolism is tightly coupled to changes in the
intracellular redox state (Locasale and Cantley, 2011), we expect a func-
tional linkage between immune activation, glucose metabolism and
redox signaling in HIV-infected lymphocytes and macrophages. Earlier
studies have shown an increase in reactive oxygen species (ROS) and
a decrease in antioxidant levels (e.g., glutathione [GSH], thioredoxin
[TRX]) in both HIV-infected cells and the plasma of asymptomatic pa-
tients during the early phase of the infection (Perl and Banki, 2000).
Subsequently, it was found that redox signaling plays an important
role in regulating gene transcription of HIV-1 throughmodulation of ac-
tivity of redox-sensitive transcription factors such as NF-κB, AP-1, and
p53 (Jones and Peterlin, 1994; Pereira et al., 2000), as well as regulation
of cellular susceptibility of apoptosis (Banki et al., 1998). A continued
increase in oxidative stress during the acute phase of HIV-1 infection ul-
timately results in the loss ofmitochondrialmembrane potential and in-
duction of apoptosis (Banki et al., 1998). It appears that the low degree
of oxidative stress is essential for initial replication of HIV-1, however,
long-lasting oxidative stress at the later stages is required to infect by-
stander cells and promote apoptosis.
Studies have indicated that the perturbation in intracellular redox
environment in HIV is linked to changes in proinﬂammatory cytokine
and chemokine levels. For example, an increase in the levels of proin-
ﬂammatory cytokines such as IL-1, TNF, and IL-17 in HIV-infected indi-
viduals correlated with an increased generation of free radicals (Morris
et al., 2012). IL-1 in its receptor-bound form activates the expression
of various other proinﬂammatory cytokines such as IL-6, IL-8 or TNF
via the NF-κB system (Merrill et al., 1989). Further, both IL-1 and TNF
production is mediated by either HIV infection or a physical association
between gp120 and CD4+ molecules on mononuclear phagocytes
(Merrill et al., 1989). Additionally, studies have shown a strong correla-
tion between increased TGF-β and IL-1 production and a decrease in the
expression of GSH biosynthetic genes and increased ROS production in
macrophages of HIV-infected individuals (Morris et al., 2012; Franklin
et al., 2003). Increased production of IL-17 in HIV-infected individuals
may play a signiﬁcant role in disease pathogenesis as it is known to in-
duce the production of antimicrobial peptides and activate the secretion
of IL-6, CCL-2, and TNF (Crome et al., 2010; Chang and Dong, 2007).
38 C.S. Palmer et al. / EBioMedicine 6 (2016) 31–41Abnormal levels of IL-17may have both beneﬁcial and adverse inﬂu-
ence onHIV-infected patients. For example, high levels of IL-17 promote
several inﬂammatory diseases such as asthma, multiple sclerosis, and
arthritis, whereas low levels impair host defense against opportunistic
pathogens such as Mycobacterium tuberculosis (Mtb) (Crome et al.,
2010). TNF, another proinﬂammatory cytokine is increased in the
serum of virally-suppressed HIV-infected persons and is associated
with the proatherogenic phenotype of monocytes (Maisa et al., 2015).
Increased generation of free radicals, oxidized lipids levels, and oxidized
glutathione (GSSG) or decreased reduced glutathione (GSH) alongwith
enhanced levels of proinﬂammatory cytokines, indicate that the break-
down in GSH homeostasis in HIV-infected individuals can be a result of
chronic overproduction of inﬂammatory cytokines (Morris et al., 2012;
Merrill et al., 1989). It is possible that chronic inﬂammation leads to an
increased generation of free radicals, which leads to production of pro-
inﬂammatory cytokines, which can further deplete GSH pool resulting
in an overwhelming increase in ROS production. Until recently, the
link between chronic inﬂammation and oxidative stress was not direct-
ly established. However, a recent study has shown that inﬂammatory
macrophages release several GSH-coupled (glutathionylated) redox-
active proteins. One of these glutathionylated proteins, peroxiredoxin-
2 (PRDX-2), induces an oxidative cascade by triggering the production
of TNF, thereby creating a self-promoting oxidative loop to induce fur-
ther inﬂammation (Salzano et al., 2014). Interestingly, we have recently
showed that HIV activation canmodulate the expression of several GSH
biosynthesis and peroxiredoxin genes (Bhaskar et al., 2015). These
ﬁndings serve to indicate an important role of GSH homeostasis and in-
ﬂammation in HIV pathogenesis.
4.2. Regulatory Dynamics Between Redox Homeostasis and Glucose
Metabolism
To understand the importance of redox and inﬂammation, it is
essential to understand how redox signaling is regulated during HIV
infection. In this context, recent studies have indicated a direct role
of central metabolism in controlling the redox state of HIV-infected
cells. Studies have indicated an enhanced expression of glucose trans-
porter Glut1 in HIV-1 infected H9 cells and in HIV-infected neuronal
tissues (Sorbara et al., 1996; Kovitz and Morgello, 1997). Although no
direct mechanistic link between oxidative stress and Glut1 expression
exists in the context of HIV-infected cells, ROS production and
evidence of increased oxidative stress have been demonstrated in
macrophage-overexpressing Glut1 (Freemerman et al., 2014). Since
HIV-infected cells display oxidative stress, it poses the questionwhether
a direct link between glucose utilization and oxidative stress exists
in HIV-infected cells. To protect against oxidative stress, the majority
of cells exploit GSH as the major source of reducing equivalent under
diverse patho-physiological conditions. However, it appears that de
novo synthesis of GSH is compromised due to cysteine deﬁciency in
HIV-infected patients (Nguyen et al., 2014). Consistent with this, intra-
cellular levels of GSH were signiﬁcantly diminished in both CD4+ and
CD8+ T cells (Roederer et al., 1991). In addition, an increase in GSSG
was also reported in HIV-1 infected CD4+ T-cells, indicating a general
decrease in intracellular reductive capacity (Aukrust et al., 1995).
Since regeneration of GSH will be dependent on the NADPH-mediated
reduction of GSSG by GSH reductase (GR), the observed increase in
glucose intake in HIV-infected donors could promote increase ﬂux
of glucose into the oxidative branch of the pentose phosphate path-
way (PPP) to produce excess NADPH for GR-catalyzed GSSG reduction
(discussed below).
At a regulatory level, glucose metabolism is controlled mainly by
changes in Glut1 expression. Glut1 expression was found to be induced
by oxidative stress (Andrisse et al., 2014), indicating that ROS can serve
as a physiologically relevant signal to induce glucose metabolism of
HIV-1 infected cells. Since high levels of glucose are known to induce
oxidative stress in a variety of cells including lymphocytes, monocytes,and epithelial cells (Lan et al., 2013; Yao et al., 2006;Wu et al., 2009), it
appears that regulatory mechanisms controlling the ﬂux of glucose in
PPP pathway to generate the necessary reductants (such as NADPH)
for GSH-mediated detoxiﬁcation of ROS might play a critical role in
modulating the intracellular redox state to control HIV replication, per-
sistence, and spread. The efﬁciency of NADPH production in the PPP
cycle is dependent upon the expression of glucose-6-phosphate dehy-
drogenase (G6PD) and transaldolase (TAL). Over-expression of TAL
reduces G6PD, NADPH, and GSH, rendering the cells susceptible to
apoptosis induced by TNF, FAS signaling, and nitric oxide (NO), while
repression of TAL activity inhibits apoptosis (Banki et al., 1996). Consis-
tent with these ﬁndings, over-expression of TAL was shown to enhance
HIV-induced oxidative stress and cell death in CD4+ T-cell lines, while
repression had an opposing effect (Banki et al., 1996).
In addition tomodulating intracellular redox environment, high glu-
cose intakewas found to enhanceHIV entry into T cells by up-regulation
of CXCR4 (Lan et al., 2013). Moreover, it has been shown that high glu-
cose intake stimulated ROS generation in T cells, which induced the
expression of CXCR4 by up-regulating HIF-1α, thereby resulted in en-
hanced HIV entry (Lan et al., 2013). Additionally, high glucose intake
was shown to enhance the expression of proinﬂammatory cytokines
such as TNF and IL-1β in monocytic cells. Both of these cytokines are
known to increase HIV replication (Lan et al., 2013). Further, oxygen
concentration and IL-7 levels appeared to modulate HIV infection by
controlling Glut1 expression. Under physiologically relevant oxygen
concentrations (5% oxygen tension), IL-7 stimulates HIV infection possi-
bly through up-regulation of Glut1 (Loisel-Meyer et al., 2012). Since
varying oxygen levels has a direct effect on GSH metabolism and intra-
cellular ROS levels, it appears that IL-7 mediated regulation of Glut1
pathway andHIV permissiveness can also beunder the control of the in-
tracellular redox state of immune cells. However, the link between IL-7,
O2 tension, Glut1 and redox needs further experimentation.4.3. Dynamic Changes in Intracellular Glutathione Redox Potential (EGSH)
Modulates HIV Persistence and Activation
The ﬁndings discussed above indicate that redox signaling is likely
central to HIV infection and inﬂammation. However, no systematic, ac-
curate and dynamic measurement of redox stress during HIV infection
has yet been carried out. Working towards this goal, we have recently
mapped the GSH redox potential (EGSH) of cytosol and mitochondria
of HIV-infected cells during latency and replicative phases of infection
(Bhaskar et al., 2014). Using a redox-sensitive GFP based non-invasive
biosensor of EGSH, we demonstrated an increased capacity of latently in-
fectedmonocytes and lymphocytes to tolerate oxidative insult and apo-
ptosis (Bhaskar et al., 2014). Remarkably, we provided an accurate
numerical indicator of EGSH change required to reactivate virus from la-
tency.We showed that amodest shift in EGSH (25mV) is sufﬁcient to re-
active HIV-1, suggesting the potential of purging HIV-1 reservoirs by
redox modulators without adversely impacting cell survival (Bhaskar
et al., 2014). Furthermore, we show that diverse agents of viral and bac-
terial origins such as HIV proteins Tat, and Nef, and lipids fromMtb ac-
tivate HIV-1 and induce substantial oxidative stress in the cytosol and
mitochondria of HIV-infected cells (Bhaskar et al., 2014). Our study sug-
gests that the initial phase of viral replication resulted in oxidative stress
from an increase in GSSG without signiﬁcantly affecting the cellular
ability to synthesize glutathione (GSH+GSSG). However, continuous
viral replication results in an overwhelming oxidative stress, which is
due to both decreased glutathione synthesis and compromised reduc-
tion of GSSG to GSH (Bhaskar et al., 2014). Lastly, our expression data
demonstrated that cells latently infected with HIV-1 produce higher
levels of antioxidants, whereas active viral replication is associated
with oxidative stress (Bhaskar et al., 2014). Together, we provided the
ﬁrst quantitative assessment of the role of redox stress on HIV-1 persis-
tence and replication.
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in glutathione biosynthesis and other cellular antioxidants endow cells
with an enhanced capacity to resist oxidative stress and apoptosis
during latency. However, a moderate oxidative shift in EGSH can reacti-
vate HIV-1 from persistence in latently infected cells. Active HIV-1 rep-
lication stimulated by viral proteins (Tat, Nef) or proinﬂammatory
cytokines (TNF) can generate an excessive oxidative shift in EGSH, there-
by promoting further increase in transcription from HIV-1 LTR through
redox-dependent transcription factors such as NF-κB. These processes
are likely central to the development of both AIDS and SNAEs in people
with HIV infection. We envisage that our redox biosensor technology
will be extremely useful in dissecting link between carbon metabolism,
inﬂammation and redox signaling during HIV-1 infection. A more com-
plete understanding between metabolic and immune processes will
form the basis of future therapies to optimize the health of those living
with HIV, and inform new strategies towards an HIV cure.
4.4. Immune Cell Glucose Metabolism in Other Disease Conditions
4.1.1. Epstein–Barr Virus and Flu Virus
Epstein–Barr virus (EBV) is an oncogenic herpesvirus that exhibits
a transient period of hyper-proliferation and a growth arrest phase
that prevents outgrowth of infected cells. Recent work by McFadden
and colleagues demonstrated that EBV-infected B-cells arrested after
the early proliferation phase have reduced levels of mitochondrial res-
piration, decrease expression of genes TCA cycle genes, lower oxidative
phosphorylation and reduced mTOR signaling. Notably, autophagy was
also increased, a phenomenon important for cell survival and mainte-
nance of early hyperproliferation during metabolic stress. On the con-
trary, long-term outgrowth was associated with increases glucose
uptake and surface Glut1 levels, resulting in elevated glycolysis, oxida-
tive phosphorylation, and suppressed basal autophagy (McFadden
et al., 2016).
Although there is limited research evaluating the direct impact
of viral infections on immune cell metabolism in humans, one recent
study showed that intranasal vaccination of human volunteers with
live inﬂuenza virus increased glycolysis in circulating plasmacytoid den-
dritic cells (pDCs). This metabolic pathway was shown to regulate pDC
antiviral functions, including IFN-α production and phenotypicmatura-
tion, demonstrating for the ﬁrst time the unrecognized role formetabo-
lism in regulating pDC immune responses to viral infections in humans
(Bajwa et al., 2016).
4.1.2. Sepsis
As outlined above, efﬁcient glucose inﬂux is essential for optimal
functions of monocytes and macrophages to support host responses
to bacterial infection. Glucose transport via Glut1 by macrophages is
required to promote ingestion of Pseudomonas aeruginosa, an impor-
tant respiratory tract pathogen in individuals with cystic ﬁbrosis
(Barghouthi et al., 1995). In a mouse model of sepsis, increased glu-
cose uptake and Glut1 expression occurred in macrophages following
P. aeruginosa infection and LPS challenge (Gamelli et al., 1996).
5. Conclusion
Increased glucose metabolism in CD4+ T cells and monocytes is a
hallmark of HIV infection and is driven by HIV proteins and inﬂamma-
tory responses. This heightened metabolic state is regulated by Glut1
and required to maintain activation of CD4+ T cells, making them
preferential targets for HIV infection and replication. Immune activa-
tion and reduced CD4+ T cell counts in HIV infected individuals
are associated with increased expression of the glucose transporter
Glut1 on CD4+ T cells. Increased glycolytic metabolism of monocytes
is proposed as an underlying mechanism in the development of
SNAEs such as frailty, cardiovascular complications and diabetes. We
have highlighted the role of oxidative stress in HIV diseasepathogenesis, noting that diminished levels of glutathione, a key mito-
chondrial antioxidant, is observed in HIV+ individuals. Understanding
the associations between metabolic dysfunction and oxidative stress
in immune cells may provide an opportunity to involve antioxidant
therapies in the care and management of HIV-associated co-
morbidities (Nguyen et al., 2014).
There has recently also have been increased interest in the role of
immunometabolism in the context of viral infections more generally.
The concept of manipulating glycolysis and oxidative phosphorylation,
a model already under investigation in cancer, to potentially impact im-
mune cell survival and functions could be applied in the future develop-
ment of novel potential forms of immunotherapy.
6. Outstanding Questions
Despite the evidence that increased glycolyticmetabolism is an hall-
mark of pro-inﬂammatorymonocytes andmacrophages, a casualmech-
anistic link between metabolically active monocytes/macrophages and
HIV-associated co-morbidities in HIV+ individuals on suppressive
ART has yet to be shown. Establishing such a link will provide novel
opportunities to predict, diagnose, and treat a constellation of age-
associated co-morbidities in HIV-infected individuals. Identifying the
physiological inducers of dysfunctional immune cell metabolism, in-
cluding understanding the relationship between oxidative stress and
metabolism requires substantial work. The body of work reviewed
here additionally raises questions of whether altering glucose metabo-
lism in HIV reservoir cells may be an important facet of future HIV erad-
ication strategies, and whether normalization of T cell metabolism can
improve immune reconstitution and immunity in HIV-infected persons.
7. Search Strategy and Selection Criteria
We conducted a literature search of the PubMed electronic database
for relevant articles; the key search terms used were “HIVmetabolism”,
“HIV Glut1”, “HIV T cell metabolism” “HIV monocyte metabolism” “HIV
macrophage metabolism”, “Immunometabolism”, “HIV CD4 metabo-
lism”, “HIV oxidative stress”, “Inﬂammation T cell metabolism”, and
“Inﬂammation monocyte metabolism” We also conducted searches in
different combinations without including HIV. Except for seminal arti-
cles, we included only those published between 2006 and February,
2016. Approximately 90% of referenced articles were published within
this period, with 70% within the last 5 years.
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